Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Neurogene (NGNE) Cash from Operations: 2018-2025

Historic Cash from Operations for Neurogene (NGNE) over the last 5 years, with Sep 2025 value amounting to -$19.5 million.

  • Neurogene's Cash from Operations fell 25.34% to -$19.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$77.2 million, marking a year-over-year decrease of 10.30%. This contributed to the annual value of -$70.6 million for FY2024, which is 37.30% down from last year.
  • Latest data reveals that Neurogene reported Cash from Operations of -$19.5 million as of Q3 2025, which was down 0.37% from -$19.4 million recorded in Q2 2025.
  • In the past 5 years, Neurogene's Cash from Operations ranged from a high of -$9.3 million in Q2 2023 and a low of -$21.7 million during Q1 2024.
  • Its 3-year average for Cash from Operations is -$16.5 million, with a median of -$16.9 million in 2023.
  • As far as peak fluctuations go, Neurogene's Cash from Operations tumbled by 70.35% in 2024, and later grew by 4.15% in 2025.
  • Neurogene's Cash from Operations (Quarterly) stood at -$16.9 million in 2023, then decreased by 3.39% to -$17.5 million in 2024, then decreased by 25.34% to -$19.5 million in 2025.
  • Its last three reported values are -$19.5 million in Q3 2025, -$19.4 million for Q2 2025, and -$20.8 million during Q1 2025.